The role of PSMA-based radioligand therapy in hormone-sensitive prostate cancer
European Journal of Nuclear Medicine and Molecular Imaging · 2025-06 · 52 (7) · 2723-2735
DOI: 10.1007/s00259-025-07083-8 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 12.02.2025. Verfasst von Riccardo Laudicella und 13 weiteren Autor:innen. Beteiligte Einrichtung: Nuclear Medicine, Department of Biomedical and Dental Sciences and Morpho-Functional Imaging, University of Messina, Messina, Italy. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Glutamate Carboxypeptidase II, Antigens, Surface, Radiopharmaceuticals. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Zurich.
Abstract (Originalsprache)
Purpose
Conventional systemic therapies are valuable options in prostate cancer (PCa); however, such treatments can determine adverse events and toxicity. The observed improvement in overall survival, coupled with PSA reduction and a favorable safety profile in the post-taxane castration-resistant PCa (CRPC) setting has prompted the consideration of PSMA-based radioligand therapy (RLT) earlier in the treatment sequence. In this review, we will describe the literature and ongoing clinical trials regarding the use of PSMA-based RLT in hormone-sensitive PCa (HSPC) including the neoadjuvant, de-novo/synchronous metastatic, adjuvant, and early BCR settings.
Methods
We performed a systematic literature search on the PubMed/MEDLINE/EMBASE and clinicaltrials.gov databases for studies and protocols assessing the role of PSMA-based RLT in HSPC.
Results
The literature search yielded 140 results. After screening titles and abstracts and applying inclusion and exclusion criteria, we selected 25 papers showing the potentialities of earlier RLT in HSPC, with several ongoing trials.
Conclusion
Early use of PSMA-based RLT holds significant potential in HSPC patients from the neoadjuvant to the BCR setting. In these stages, the lower tumor burden, more frequent exclusive nodal involvement, and higher organ reserve may improve treatment efficacy and allow for treatment combinations while maintaining a less toxic profile.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Nuclear Medicine, Department of Biomedical and Dental Sciences and Morpho-Functional Imaging, University of Messina, Messina, Italy.
- IRCCS Ospedale Policlinico San Martino, Genova, Italy.
- Nuclear Medicine, Department of Health Sciences (DISSAL), University of Genova, Genova, Italy.
- Department of Nuclear Medicine, University Hospital Zürich, University of Zurich, Zurich, Switzerland. irene.burger@ksb.ch.
- Department of Nuclear Medicine, Cantonal Hospital Baden, affiliated Hospital for Research and Teaching, University of Zurich, Baden, Switzerland. irene.burger@ksb.ch.
- Brain Mapping Lab, Department of Biomedical, Dental Sciences and Morphological and Functional Imaging, University of Messina, Messina, Italy.
ORCID-Profile: Riccardo Laudicella, Matteo Bauckneht, Irene A Burger, Andrea Farolfi, Virginia Liberini
Förderung
- University of Zurich
Zitieren
APA
Laudicella, R., Bauckneht, M., Burger, I. A., Cacciola, A., Fanti, S., Farolfi, A., Ficarra, V., Iagaru, A., Liberini, V., Pergolizzi, S., Santo, G., Virgolini, I., Minutoli, F., & Baldari, S. (2025). The role of PSMA-based radioligand therapy in hormone-sensitive prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 52(7), 2723-2735. https://doi.org/10.1007/s00259-025-07083-8
Vancouver
Laudicella R, Bauckneht M, Burger IA, Cacciola A, Fanti S, Farolfi A, et al. The role of PSMA-based radioligand therapy in hormone-sensitive prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging. 2025;52(7):2723-2735. doi:10.1007/s00259-025-07083-8
BibTeX
@article{Laudicella2025,
author = {Laudicella, Riccardo and Bauckneht, Matteo and Burger, Irene A and Cacciola, Alberto and Fanti, Stefano and Farolfi, Andrea and Ficarra, Vincenzo and Iagaru, Andrei and Liberini, Virginia and Pergolizzi, Stefano and Santo, Giulia and Virgolini, Irene and Minutoli, Fabio and Baldari, Sergio},
title = {The role of PSMA-based radioligand therapy in hormone-sensitive prostate cancer},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2025},
volume = {52},
number = {7},
pages = {2723--2735},
doi = {10.1007/s00259-025-07083-8}
}
EUVIMED